<i>MTARC1</i> and <i>HSD17B13</i> Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery
The severity of hepatic steatosis is modulated by genetic variants, such as patatin-like phospholipase domain containing 3 (<i>PNPLA3</i>) rs738409, transmembrane 6 superfamily member 2 (<i>TM6SF2</i>) rs58542926, and membrane-bound O-acyltransferase domain containing 7 (<...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/24/15825 |
| Summary: | The severity of hepatic steatosis is modulated by genetic variants, such as patatin-like phospholipase domain containing 3 (<i>PNPLA3</i>) rs738409, transmembrane 6 superfamily member 2 (<i>TM6SF2</i>) rs58542926, and membrane-bound O-acyltransferase domain containing 7 (<i>MBOAT7</i>) rs641738. Recently, mitochondrial amidoxime reducing component 1 (<i>MTARC1</i>) rs2642438 and hydroxysteroid 17-beta dehydrogenase 13 (<i>HSD17B13</i>) rs72613567 polymorphisms were shown to have protective effects on liver diseases. Here, we evaluate these variants in patients undergoing bariatric surgery. A total of 165 patients who underwent laparoscopic sleeve gastrectomy and intraoperative liver biopsies and 314 controls were prospectively recruited. Genotyping was performed using TaqMan assays. Overall, 70.3% of operated patients presented with hepatic steatosis. NASH (non-alcoholic steatohepatitis) was detected in 28.5% of patients; none had cirrhosis. The increment of liver fibrosis stage was associated with decreasing frequency of the <i>MTARC1</i> minor allele (<i>p</i> = 0.03). In multivariate analysis <i>MTARC1</i> was an independent protective factor against fibrosis ≥ 1b (OR = 0.52, <i>p</i> = 0.03) and ≥ 1c (OR = 0.51, <i>p</i> = 0.04). The <i>PNPLA3</i> risk allele was associated with increased hepatic steatosis, fibrosis, and NASH (OR = 2.22, <i>p</i> = 0.04). The <i>HSD17B13</i> polymorphism was protective against liver injury as reflected by lower AST (<i>p</i> = 0.04) and ALT (<i>p</i> = 0.03) activities. The <i>TM6SF2</i> polymorphism was associated with increased ALT (<i>p</i> = 0.04). In conclusion, hepatic steatosis is common among patients scheduled for bariatric surgery, but the <i>MTARC1</i> and <i>HSD17B13</i> polymorphisms lower liver injury in these individuals. |
|---|---|
| ISSN: | 1661-6596 1422-0067 |